ATAI Looks To Raise $US100 Million In Float

Here’s the latest .. we’re pretty sure we’ll all hearing more about this !


  • Peter Thiel-backed Atai Life Sciences is planning to raise $100 million in an initial public offering.
  • The clinical-stage biopharmaceutical company has raised $362 million from private investors so far, SEC filings show.
  • Atai partners with companies that research the use of psychedelic compounds to treat mental health conditions.

Health start-up Atai Life Sciences is planning to raise $100 million in an initial public offering, according to filings submitted to the US Securities and Exchange Commission on Tuesday.

The clinical-stage biopharmaceutical company that’s backed by billionaire investor Peter Thiel has raised an aggregate of $362 million from private investors so far, the filings show.

Atai describes itself as a drug development platform that aims to incubate, acquire, and invest in companies that advance mental health disorder treatments. Some of the companies that Atai currently partners with use psychedelic compounds to develop drugs.

Atai said it currently has 10 therapeutic programs, including five psychedelic compounds, in its pipeline, and six enabling technologies in development. None of Atai’s drugs have been formally approved by regulators but one of the companies has initiated a Phase 2 trial in the US.


Cannabis Law Report Has Been Publishing Legal, Professional & Regulated
Cannabis News Daily Since 2016 – All For Free

We want to carry on providing the important cannabis sector
news for free for all our readers.

Costs are rising to produce Cannabis Law Report and we’d like to ask you,
our readers, for a small donation.

Primary Sponsor

Cannabis Banking - FinCann

New: Free USA Cannabis Case Law Search – New Cases Daily

Directory Categories

Karma Koala Podcast

Sponsor – aBizinaBox

Top Marijuana Blog
%d bloggers like this: